OVID

Ovid Therapeutics Inc. [OVID] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

OVID Stock Summary

Top 10 Correlated ETFs

OVID


Top 10 Correlated Stocks

OVID


In the News

08:00 29 Mar 2024 OVID

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a panel titled “Orphan Epilepsies” at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. ET in Boston, Massachusetts.

08:00 29 Mar 2024 OVID

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.

07:30 29 Mar 2024 OVID

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida.

01:33 29 Mar 2024 OVID

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why

Ovid Therapeutics (OVID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

07:30 29 Mar 2024 OVID

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York.

09:38 29 Mar 2024 OVID

3 Very Promising Penny Stocks That Are Flying Under the Radar

Warning: while this discussion obviously centers on penny stocks to buy, this subsegment of the market carries astounding risks. While it's difficult to verify, one source has the failure rate of these speculative, low-market capitalization entities as over 90%.

10:32 29 Mar 2024 OVID

Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.

02:12 29 Mar 2024 OVID

Ovid Therapeutics: Bullish Outlook Strengthened By Positive 2-Year Open-Label Trial Results

Ovid Therapeutics' TAK-935 has a high potential for positive Phase 3 clinical trial results for both Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). Significant Revenue Potential. The median annual cost of orphan-designated therapy is approximately $218,000. The estimated total addressable market for TAK-935 includes approximately 159,000 patients with DS and LGS across the US, EU, and Japan.

09:54 29 Mar 2024 OVID

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.23 per share a year ago.

01:42 29 Mar 2024 OVID

Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know

Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OVID Financial details

Company Rating
Sell
Market Cap
226.27M
Income
1.48B
Revenue
391.69K
Book val./share
1.24
Cash/share
1.5
Dividend
-
Dividend %
-
Employees
40
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
0.15
Forward P/E
-17.11
PEG
-0
P/S
739.21
P/B
2.16
P/C
2.05
P/FCF
-5.07
Quick Ratio
10.05
Current Ratio
10.59
Debt / Equity
0.36
LT Debt / Equity
0.34
-
-
EPS (TTM)
21.1
EPS next Y
-0.18
EPS next Q
-0.23
EPS this Y
1.37%
EPS next Y
-100.88%
EPS next 5Y
-101.39%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
29.91%
EPS Q/Q
37.5%
-
-
-
-
SMA20
-25%
SMA50
-
SMA100
-
Inst Own
55.11%
Inst Trans
0.95%
ROA
1190%
ROE
1279%
ROC
-0.46%
Gross Margin
84402%
Oper. Margin
-17970%
Profit Margin
501877%
Payout
-
Shs Outstand
70.71M
Shs Float
58.55M
-
-
-
-
Target Price
-
52W Range
2.4-4.139
52W High
-23%
52W Low
+54%
RSI
48
Rel Volume
0.4
Avg Volume
204.83K
Volume
80.98K
Perf Week
10.39%
Perf Month
-15.38%
Perf Quarter
-16.3%
Perf Half Y
-17.65%
-
-
-
-
Beta
0.715
-
-
Volatility
0.06%, 0.34%
Prev Close
0.98%
Price
3.08
Change
0.98%

OVID Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.223.090.020.01
Net income per share
-1.51-1.381.82-0.73-0.74
Operating cash flow per share
-1.3-0.881.76-0.79-0.65
Free cash flow per share
-1.31-0.891.75-0.81-0.65
Cash per share
1.961.242.783.031.5
Book value per share
1.790.752.661.881.24
Tangible book value per share
1.770.742.661.881.24
Share holders equity per share
1.790.752.661.881.24
Interest debt per share
0000.20.44
Market cap
162.75M134.67M216.61M130.85M227.27M
Enterprise value
120.85M62.64M28.81M18.38M246.23M
P/E ratio
-2.75-1.671.76-2.55-4.34
Price to sales ratio
010.671.0487.07580.22
POCF ratio
-3.19-2.611.83-2.37-4.96
PFCF ratio
-3.17-2.591.83-2.31-4.95
P/B Ratio
2.323.091.210.992.59
PTB ratio
2.323.091.210.992.59
EV to sales
04.960.1412.23628.63
Enterprise value over EBITDA
-1.97-0.770.23-0.33-4.27
EV to operating cash flow
-2.37-1.210.24-0.33-5.38
EV to free cash flow
-2.35-1.210.24-0.32-5.36
Earnings yield
-0.36-0.60.57-0.39-0.23
Free cash flow yield
-0.32-0.390.55-0.43-0.2
Debt to equity
0000.130.36
Debt to assets
0000.110.22
Net debt to EBITDA
0.680.88-1.512.02-0.33
Current ratio
7.583.3912.8718.799.55
Interest coverage
00020.120
Income quality
0.850.640.971.020.87
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
02.430.1821.5879.36
Research and developement to revenue
05.030.2316.3871.91
Intangibles to total assets
0.010000
Capex to operating cash flow
00.0100.030
Capex to revenue
0-0.030-0.94-0.35
Capex to depreciation
-0.96-1.27-0.8-1.03-0.09
Stock based compensation to revenue
00.60.024.3618.6
Graham number
7.794.8310.455.564.56
ROIC
-0.86-1.860.68-0.32-0.44
Return on tangible assets
-0.74-1.070.63-0.33-0.36
Graham Net
1.70.682.562.70.7
Working capital
69.28M52.78M175.68M124.39M98.12M
Tangible asset value
69.56M43.31M179.58M132.05M87.61M
Net current asset value
68.99M42.55M175.68M108.39M53.37M
Invested capital
0000.130.36
Average receivables
565.57K636.45K70.88K00
Average payables
3.51M4.35M6.29M4.54M2.83M
Average inventory
00000
Days sales outstanding
04.1000
Days payables outstanding
4.66K00515.93846.54
Days of inventory on hand
00000
Receivables turnover
089000
Payables turnover
0.08000.710.43
Inventory turnover
00000
ROE
-0.85-1.850.68-0.39-0.6
Capex per share
-0.01-0.010-0.020

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.1621.66-0.18-0.16-0.22
Operating cash flow per share
-0.13-0.17-0.17-0.14-0.17
Free cash flow per share
-0.13-0.17-0.17-0.14-0.17
Cash per share
3.021.67K1.41.241.5
Book value per share
1.881.721.611.441.24
Tangible book value per share
1.871.721.61.441.24
Share holders equity per share
1.881.721.611.441.24
Interest debt per share
0.22-10.190.240.230.44
Market cap
131.08M181.36M226.11M270.06M227.61M
Enterprise value
18.61M-62.07B170.82M228.92M246.57M
P/E ratio
-2.860.03-4.56-6-3.71
Price to sales ratio
2.83K2.74K3.01K2.48K1.61K
POCF ratio
-14.29-14.97-19.32-26.87-19.11
PFCF ratio
-14.19-14.96-19.12-26.85-19.11
P/B Ratio
0.991.52.042.672.59
PTB ratio
0.991.52.042.672.59
EV to sales
402.19-938.13K2.28K2.1K1.74K
Enterprise value over EBITDA
-1.534.17K-12.4-19.69-13.86
EV to operating cash flow
-2.035.12K-14.59-22.78-20.7
EV to free cash flow
-2.015.12K-14.45-22.76-20.7
Earnings yield
-0.098.4-0.05-0.04-0.07
Free cash flow yield
-0.07-0.07-0.05-0.04-0.05
Debt to equity
0.136.780.150.160.36
Debt to assets
0.115.720.120.130.22
Net debt to EBITDA
9.244.18K4.013.54-1.07
Current ratio
18.7917.7810.0710.599.55
Interest coverage
11.50.01000
Income quality
0.80.910.940.890.78
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
144.2126.11109.9762.4554.32
Research and developement to revenue
119.8299.9879.9848.9474.46
Intangibles to total assets
00000
Capex to operating cash flow
0.0100.0100
Capex to revenue
-1.36-0.2-1.57-0.05-0.01
Capex to depreciation
-0.14-0.03-0.3-0.010
Stock based compensation to revenue
37.3728.9725.9814.9712.64
Graham number
2.6228.962.552.282.46
ROIC
-0.070.97-0.1-0.09-0.14
Return on tangible assets
-0.0710.64-0.09-0.09-0.11
Graham Net
2.71.67K1.030.90.7
Working capital
124.39M112.8B92.03M83.05M98.12M
Tangible asset value
132.05M120.76M110.44M101.07M87.61M
Net current asset value
108.39M119.5B76.64M67.98M53.37M
Invested capital
0.136.780.150.160.36
Average receivables
00000
Average payables
1.49M916.72M917.63M2.49M2.46M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
399.5-2.49K-4.52-1.01830.27
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.23-0.04-19.91-89.480.11
Inventory turnover
00000
ROE
-0.0912.59-0.11-0.11-0.17
Capex per share
00000

OVID Frequently Asked Questions

What is Ovid Therapeutics Inc. stock symbol ?

Ovid Therapeutics Inc. is a US stock , located in New york of Ny and trading under the symbol OVID

What is Ovid Therapeutics Inc. stock quote today ?

Ovid Therapeutics Inc. stock price is $3.08 today.

Is Ovid Therapeutics Inc. stock public?

Yes, Ovid Therapeutics Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap